Cormedix Inc. · NASDAQ:CRMD
Cormedix — Investor Presentation (March 2026)
23 slides from Cormedix's investor presentation, Mar 6, 2026
Slide 1: Corporate Presentation March 2026
NOT FOR DISTRIBUTION WITHOUT THE PRIOR WRITTEN PERMISSION OF CORMEDIX THERAPEUTICS Corporate Presentation March 2026 CorMedix Therapeutics
Slide 2: Forward-looking statements
NOT FOR DISTRIBUTION WITHOUT THE PRIOR WRITTEN PERMISSION OF CORMEDIX THERAPEUTICS 2 This presentation contains “forward - looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 , Section 27 A of the Securities Act, and Section 21 E of the Exchange Act of 1934
Slide 3: Introduction
NOT FOR DISTRIBUTION WITHOUT THE PRIOR WRITTEN PERMISSION OF CORMEDIX THERAPEUTICS Introduction 3
Slide 4: CorMedix Therapeutics is a commercial pharmaceutical company
NOT FOR DISTRIBUTION WITHOUT THE PRIOR WRITTEN PERMISSION OF CORMEDIX THERAPEUTICS 4 CorMedix Therapeutics is a commercial pharmaceutical company focused on providing innovative products for institutional markets has a diversified portfolio of specialty injectable therapies that is built upon a scal
Slide 5: Proven leadership team with a long track record of commercial outperformance
NOT FOR DISTRIBUTION WITHOUT THE PRIOR WRITTEN PERMISSION OF CORMEDIX THERAPEUTICS 5 CorMedix Therapeutics has a proven leadership team with a long track record of commercial outperformance PRIOR EXPERIENCE JOINED CORMEDIX THERAPEUTICS Joe Todisco Chairman & Chief Executive Officer 2022 • Chief Comm
Slide 6: Financial highlights
NOT FOR DISTRIBUTION WITHOUT THE PRIOR WRITTEN PERMISSION OF CORMEDIX THERAPEUTICS 6 Financial highlights * Per CorMedix 10K as of March 2, 2026 ** Excludes restricted cash (1) Pro Forma Net Revenue was prepared by combining the estimated financial results and for CorMedix and Melinta for the full f
Slide 7: The combined portfolio is diversified and complementary
NOT FOR DISTRIBUTION WITHOUT THE PRIOR WRITTEN PERMISSION OF CORMEDIX THERAPEUTICS Product Class Current Therapeutic Area Product Taurolidine and heparin catheter lock solution CRBSI Echinocandin antifungal Candidemia and invasive candidiasis Tetracycline antibacterial Serious infections including A
Slide 8: Our Products
NOT FOR DISTRIBUTION WITHOUT THE PRIOR WRITTEN PERMISSION OF CORMEDIX THERAPEUTICS Our Products 8
Slide 9: DefenCath positioned to capture value across outpatient and inpatient markets
NOT FOR DISTRIBUTION WITHOUT THE PRIOR WRITTEN PERMISSION OF CORMEDIX THERAPEUTICS 9 DefenCath is well positioned to capture significant value across both outpatient and inpatient markets Source: CorMedix market research. DefenCath launched full scale for hemodialysis in July 2024 Strong commercial
Slide 10: DefenCath first and only FDA-approved catheter lock solution with CRBSI risk reduction
NOT FOR DISTRIBUTION WITHOUT THE PRIOR WRITTEN PERMISSION OF CORMEDIX THERAPEUTICS 0.46 0.13 0.0 0.2 0.4 0.6 Control (n=397) DefenCath (n=397) CRBSIs per 1,000 CD 10 DefenCath is the first and only FDA - approved catheter lock solution with significant risk reduction in catheter - related bloodstrea
Slide 11: DefenCath – US Renal Care real world evidence interim results
NOT FOR DISTRIBUTION WITHOUT THE PRIOR WRITTEN PERMISSION OF CORMEDIX THERAPEUTICS 11 DefenCath – US Renal Care positive real world evidence interim results Design Retrospective analysis of outpatients receiving dialysis through a CVC at USRC • 23,663 patients in pre - intervention (July 1, 2022 – J
Slide 12: REZZAYO next generation echinocandin with once-weekly dosing
NOT FOR DISTRIBUTION WITHOUT THE PRIOR WRITTEN PERMISSION OF CORMEDIX THERAPEUTICS Next generation echinocandin with once - weekly dosing schedule – highly simplifies management of candidemia and invasive candidiasis Strong commercial uptake – On formulary at 55+ large health systems – 100+ new acco
Slide 13: Melinta portfolio: KIMYRSA/ORBACTIV, and other antibacterials
NOT FOR DISTRIBUTION WITHOUT THE PRIOR WRITTEN PERMISSION OF CORMEDIX THERAPEUTICS • Differentiated triple MOA that treats ABSSSI caused by gram - positive pathogens in adult patients – Single, one - time infusion avoids burden of multi - dose infusions and ensures adherence without requiring a PICC
Slide 14: Expansion & Growth Opportunities
NOT FOR DISTRIBUTION WITHOUT THE PRIOR WRITTEN PERMISSION OF CORMEDIX THERAPEUTICS Expansion & Growth Opportunities 14
Slide 15: Positioned to create value as a diversified specialty pharma business
NOT FOR DISTRIBUTION WITHOUT THE PRIOR WRITTEN PERMISSION OF CORMEDIX THERAPEUTICS 15 CorMedix Therapeutics is well positioned to continue to create value as a diversified specialty pharma business with a compelling growth path Inflecting Commercial - Stage Company Strong Initial DefenCath Launch Br
Slide 16: Development stage pipeline
NOT FOR DISTRIBUTION WITHOUT THE PRIOR WRITTEN PERMISSION OF CORMEDIX THERAPEUTICS 16 CorMedix Therapeutics development stage pipeline has potential to drive meaningful value over coming years Commercial Ph III / Registrational Ph II Ph I Pre - Clinical Therapeutic Area Expansion Product Prophylaxis
Slide 17: ReSPECT Ph III study for prophylaxis of invasive fungal infections
NOT FOR DISTRIBUTION WITHOUT THE PRIOR WRITTEN PERMISSION OF CORMEDIX THERAPEUTICS 17 Expanded indication Ph 3 study ( ReSPECT ) for prophylaxis of invasive fungal infections is underway • Study for the prevention of invasive fungal diseases in subjects undergoing allogeneic blood and marrow transpl
Slide 18: REZZAYO Prophy – Commercial Opportunity
NOT FOR DISTRIBUTION WITHOUT THE PRIOR WRITTEN PERMISSION OF CORMEDIX THERAPEUTICS ! % 7$0 $FURVV DOO KHPDWRORJ\ RQFRORJ\ DQG WUDQVSODQW SDWLHQW XVDJH 3URSK\OD[LV $GGUHVVDEOH 3DWLHQW 3RSXODWLRQ a % a % &DQGLGD $VSHUJLOOXV 3-3 $OOR $XWR $0/ 627 2WKHU 18 REZZAYO Prophy – Commercial Opportunity Expands
Slide 19: NUTRI-LOCK Ph III study for CLABSIs in adult TPN patients
NOT FOR DISTRIBUTION WITHOUT THE PRIOR WRITTEN PERMISSION OF CORMEDIX THERAPEUTICS 19 Expanded indication Ph 3 study (NUTRI - LOCK) for CLABSIs in adult TPN patients is underway Program Overview: A Ph 3, randomized, double - blind, adaptive, 2 - arm, study assessing the safety and efficacy of DefenC
Slide 20: DefenCath in Total Parenteral Nutrition
NOT FOR DISTRIBUTION WITHOUT THE PRIOR WRITTEN PERMISSION OF CORMEDIX THERAPEUTICS 20 DefenCath In Total Parenteral Nutrition • Approximately 40,000 patients in the US receiving outpatient/home TPN • CLABSIs occur in up to 26% of TPN patients with a CVC • A majority of TPN patients receive daily loc
Slide 21: Strategic investment in Talphera and financial flexibility
NOT FOR DISTRIBUTION WITHOUT THE PRIOR WRITTEN PERMISSION OF CORMEDIX THERAPEUTICS Strategic Investment in In 2025, CorMedix Therapeutics made a strategic investment in Talphera in return for the right of first negotiation . This period will be triggered by announcement of Phase III NEPHRO study res
Slide 22: Anticipated company milestones
NOT FOR DISTRIBUTION WITHOUT THE PRIOR WRITTEN PERMISSION OF CORMEDIX THERAPEUTICS 22 Anticipated company milestones 2 H 2026 / 1H 2027 1 H 2026 • CorMedix Therapeutics 1Q 2026 earnings and business updates • REZZAYO prophylaxis study clinical data • Medicare Advantage updates • Conference presence
Slide 23: CorMedix Therapeutics key highlights
NOT FOR DISTRIBUTION WITHOUT THE PRIOR WRITTEN PERMISSION OF CORMEDIX THERAPEUTICS 23 CorMedix Therapeutics key highlights Commercial specialty pharma business with portfolio of products, revenue scale, and a dynamic commercial platform in acute care poised for organic and inorganic growth 1 Portfol